



Steve Poretz, RN, MSHA
Executive Director

Pfizer CEO Thanks Clinical Alliance for Research and Education – Infectious Diseases (CARE-ID) for Vaccine Study Partnership

“An indispensable and extraordinary role in our quest to conquer this disease”

Annandale, VA; October 31, 2020 – As CARE-ID has reached its major milestone of allocated enrollees in this collaboration, the Pfizer CEO expressed his appreciation directly to our principal investigator and his team.

“On behalf of Pfizer and our leadership, I would like to personally thank you and your team[s] for your exceptional partnership over the last several months. This year has been unlike any we have ever experienced, as the COVID-19 pandemic continues to place great medical, social and economic burdens on the world. Whether you are in the United States [or other countries around the globe], we are all united in our commitment to determining whether we have a safe and effective vaccine candidate that can protect our communities from COVID-19 infection. Each of you has played an indispensable and extraordinary role in our quest to conquer this disease, and for that, we are profoundly grateful...”

“The coming weeks will continue to be crucial as we near our important data read-outs and work together on data cleaning and query resolution. It goes without saying that quality continues to be paramount, and that every day matters as we prepare for and finalize our potential Emergency Use Authorization submissions.”

“Thank you for being with us on this journey, for the quality and care you provide to each participant, and for being our valued partner[s] in hope. This appreciation extends to your [entire] team...”

“At CARE-ID we took on this important research project because of the importance of fighting the COVID-19 pandemic and because of our core mission to investigate better treatments for serious, life threatening infectious diseases”, said Donald M. Poretz, MD, FACP, FIDSA, principal study investigator, founder and senior partner of Infectious Diseases Physicians, Inc. (IDP), the private clinical practice partner of CARE-ID. “We knew at the time we took on this project we would be a valuable partner given CARE-ID’s decades long experience. Receiving such generous recognition and words of appreciation from the very top of the Pfizer organization deepens the satisfaction we feel from the work we’ve done.”

“As the Pfizer CEO stated in his letter, ‘The coming weeks will continue to be crucial as we near our important data read-outs and work on data cleaning and query resolution’, CARE-ID remains very actively involved through the final conclusion of the study”, said Stephen Poretz, RN, MSHA, CARE-ID Executive Director. “For our participants, all of them will have their follow up blood work completed within the next two weeks. That is the key data point (measuring their antibodies 3 – 4 weeks after they received their second and final injection). At that point, we will finalize all our tracking and administration study details for Pfizer. From there we will wait along with the rest of the world the results of the FDA’s review process.”

For this COVID-19 vaccine study, Pfizer established a very large team of clinical researchers in 120 clinical investigational sites around the world, including many states across the United States to accelerate enrolling and managing over a now expanded number of 44,000 volunteers who have participated in this study. “Clinical trials of this large magnitude are vital in testing potential defenses against COVID-19. These prove the worth of infectious disease clinical research in protecting significant portions of the population from diseases,” said Donald M. Poretz, MD. “CARE-ID was very pleased to once again engage with our long-standing research partner, Pfizer, to be on the front lines of the fight against COVID-19.”

CARE-ID is located and can be contacted at:

3289 Woodburn Rd. Suite 250

Annandale, Virginia 22003

info@careidresearch.com

703-560-4821 (phone)

703-641-8654 (fax)

<http://www.careidresearch.com/>

About CARE-ID

CARE-ID conducts clinical research trials in the field of infectious diseases with particular focus on the safety and confidentiality of our participants, quality of our data, and integrity of our results. We partner with pharmaceutical and biotechnology companies to develop experimental therapies for both the prevention and treatment of infectious diseases.